AstraZeneca invests $2bn in Summit to advance ADC combinations

AstraZeneca will invest $2bn in Summit and plans trials combining ivonescimab with ADCs, starting with Sone-Ve in GI cancers.

Sanofi and Regeneron expand immunology alliance

Sanofi and Regeneron are adding four long-acting antibody programs to their immunology alliance, with a $1 billion upfront payment.

Login required

Almirall presents new dermatology data at EADV 2026

Almirall will present more than 20 EADV 2026 abstracts on atopic dermatitis, psoriasis and actinic keratosis in Vienna.

Trend report finds broad support for cannabis therapy, but stigma persists

MedCanOneStop compares patient and YouGov data: acceptance of cannabis therapy is high, but stigma in care and work remains.

Nurix Achieves $7 Million Milestone in Pfizer Collaboration

Nurix will receive $7 million from Pfizer after reaching a research milestone in their degrader antibody conjugate collaboration.

Grünenthal places €850 million bond financing

Grünenthal has closed an €850 million senior secured bond financing to refinance debt and support strategic initiatives through 2032.

BioNTech to close three German sites after failed buyer search

BioNTech will close sites in Marburg, Tübingen and Idar-Oberstein. About 1,800 employees are affected after no buyers were found.

Organon calls for EU strategy on women’s health

Organon is calling for a European women’s health strategy, citing gaps in contraception access, research funding and medical data.

Grünenthal to acquire Stivarga from Bayer

Grünenthal will buy Bayer’s cancer drug Stivarga for up to €375 million. Closing is expected by late 2026 or early 2027.

Sanofi and Cheplapharm plan mature medicines partnership

Sanofi plans to transfer 20 mature medicines and three sites to Cheplapharm, receiving a 26.4 percent equity stake in return.

Sernova and Seraxis plan merger to form BetaNova Biotherapeutics

Sernova and Seraxis plan to merge their type 1 diabetes islet cell replacement programs into BetaNova Biotherapeutics in 2026.

Samsung Biologics publishes offer prospectus for PolyPeptide

Samsung Biologics has published the offer prospectus for PolyPeptide, with the main tender period expected from September 15 to October 12, 2026.

Valerio Therapeutics signs agreement to acquire Etherna

Valerio Therapeutics plans to acquire Etherna at a €30 million enterprise value and funds the deal with a €40.25 million PIPE financing.

BioMarin to acquire Alesta for HPP candidate ALE1

BioMarin will acquire Alesta Therapeutics to add ALE1, an oral Phase 1/2a candidate for hypophosphatasia, to its pipeline.

Moderna reports positive Phase 3 melanoma data

Moderna reported positive Phase 3 topline data for intismeran autogene plus pembrolizumab in adjuvant melanoma treatment.

From Anonymous Clicks to Connected HCP Journeys: Why Integrated SSO Matters in Pharma Marketing

Statutory reimbursement for cannabis flower ends without transition period

Germany's statutory reimbursement for cannabis flower ended on 30 July. An industry initiative seeks transition rules for ongoing therapies.

GSK plans new global R&D centre in Cambridge

GSK will invest £400 million in a new Cambridge R&D centre and shift UK research operations from Stevenage by 2029.

Bausch + Lomb highlights two product launches

Bausch + Lomb highlights two launches: a vitrectomy cutter for Europe and preservative-free lubricant eye drops in the United States.

argenx to acquire Forte Biosciences and expand immunology pipeline

argenx plans to acquire Forte Biosciences and add FB102, a first-in-class anti-CD122 antibody, to its immunology pipeline.